BRIEF published on 02/21/2025 at 08:35, 1 year 1 month ago Abivax to Hold Expert Webcast on Ulcerative Colitis Abivax Obefazimod Ulcerative Colitis Clinical Trial Webcast Event
BRIEF published on 02/21/2025 at 08:35, 1 year 1 month ago Abivax organise un webcast d'experts sur la rectocolite hémorragique Abivax Obefazimod Rectocolite Hémorragique Essai Clinique Webcast De L'événement
PRESS RELEASE published on 02/21/2025 at 08:30, 1 year 1 month ago Abivax organisera un webcast animé par un leader d’opinion de renom le 17 mars 2025 Abivax organise un webcast le 17 mars 2025 animé par le Dr David Rubin, expert en gastro-entérologie, pour présenter l'essai clinique de phase 3 ABTECT sur la rectocolite hémorragique Abivax Webcast Rectocolite Hémorragique Essai Clinique Dr David Rubin
PRESS RELEASE published on 02/21/2025 at 08:30, 1 year 1 month ago Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Abivax to host Key Opinion Leader (KOL) webcast featuring Dr. David Rubin on March 17, 2025, discussing ulcerative colitis treatment landscape and ABTECT Phase 3 Trial Abivax Ulcerative Colitis Webcast ABTECT Phase 3 Trial Key Opinion Leader
PRESS RELEASE published on 02/21/2025 at 08:30, 1 year 1 month ago Abivax organisera un webcast animé par un leader d’opinion de renom le 17 mars 2025 Abivax organisera un webcast animé par un leader d’opinion de renom le 17 mars 2025. Le Dr David Rubin présentera l’essai clinique pivot de phase 3 ABTECT d’Abivax Abivax Webcast Essai Clinique Phase 3 Dr David Rubin
BRIEF published on 02/18/2025 at 10:08, 1 year 1 month ago Crossing of threshold at ABIVAX: statement from Sofinnova Voting Rights Abivax Threshold Crossing Product Development Sofinnova Partners
BRIEF published on 02/18/2025 at 10:08, 1 year 1 month ago Franchissement de seuil chez ABIVAX : déclaration de Sofinnova Droits De Vote Franchissement De Seuil Abivax Développement De Produits Sofinnova Partners
PRESS RELEASE published on 02/18/2025 at 10:03, 1 year 1 month ago Franchissement de seuil et déclaration d'intention Déclaration de franchissement de seuil et déclaration d'intention par Sofinnova Partners pour ABIVAX sur Euronext Paris Euronext Paris Franchissement De Seuil Abivax Déclaration D'intention Sofinnova Partners
BRIEF published on 01/28/2025 at 08:35, 1 year 1 month ago Abivax unveils its financial calendar for 2025 Financial Results Biotechnology Half-yearly Report Financial Calendar Abivax
BRIEF published on 01/28/2025 at 08:35, 1 year 1 month ago Abivax dévoile son calendrier financier pour 2025 Résultats Financiers Biotechnologie Calendrier Financier Abivax Rapport Semestriel
Published on 03/23/2026 at 02:00, 1 hour 39 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 13:30, 2 days 14 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/22/2026 at 12:23, 15 hours 15 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 4 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 6 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 6 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 8 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 8 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 9 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 9 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
